On the stock market since 2022, it operates in the world of health and science. It has 2,495 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 11% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $477.7M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 12% a year on average.
It pays out $24.92 per share each year — regular cash for whoever holds the stock.
The company’s market value is 36 times its annual profit. Even a small disappointment could hit the price hard.
The price action doesn’t yet back an upward turn. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, BTTAY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BTTAY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.